Belgium: Broader Portfolio of Fertility Products Sasmar Acquires Aquatrove Biosiences
Sasmar Pharmaceuticals has acquired Aquatrove Biosciences, a biotechnology company focussed on discovery, research and development in human reproductive health and fertility.
Brussels/Belgium — Sasmar, through its Australian based holding, acquired all stock in privately held Aquatrove in exchange for an upfront payment of an undisclosed sum in cash. The deal formally closed this week included Aquatrove’s global portfolio of intellectual property, patents, and ownership of a rich pool of research data built up over the last 14 years.
The Belgium based company is seeking biotechnology acquisitions to bolster product pipelines. The company's President and CEO, John-Michael Mancini said ”the acquisition captures the capability and knowhow built up over many years by the specialized team at Aquatrove and facilitates the realization of our plans for growth moving forward.”
In 2008 Sasmar commercialized an Aquatrove patented formulation developed to help increase the chances of a natural pregnancy that all trying to conceive couples could easily use replacing regular personal lubricant with sexual intercourse during ovulation.